News

News

A New Era for Waldenström’s Macroglobulinemia Treatment

In the more than 70 years since Jan G. Waldenström discovered Waldenström's macroglobulinemia, there have been few answers about what causes the malignant B-cell...
WIB_icon

Childhood ALL Survivors Struggle with Obesity and Long-Term Fitness Deficits

In the past few decades, treatment of childhood acute lymphoblastic leukemia (ALL) has been recognized as one of the true success stories in hematologic...

High-Cost Surveillance Imaging Falls Short on Survival Benefit in DLBCL

Surveillance imaging to monitor patients with diffuse large B-cell lymphoma (DLBCL) in first remission may be common practice, but a new cost-effectiveness analysis has...
The Society Pages

Nominations for ASH Leadership Positions, and more

Clinical Practitioners: Nominate Yourself or a Colleague for an ASH Leadership Position ASH members in good standing can nominate themselves or other members for leadership...
WIB_icon

Entospletinib Makes Its Mark in Chronic Lymphocytic Lymphoma

Therapies that target B-cell receptor signaling kinases have made great strides in chronic lymphocytic lymphoma (CLL) and other B-cell malignancies. According to results from...
WIB_icon

How Can We Better Predict High-Risk Pregnancies for Women with SCD?

Though sickle cell disease (SCD) is associated with significant lifetime morbidity and premature mortality, better quality of care has led to improved survival, with...

How Costly is Febrile Neutropenia in Patients with Metastatic Cancer?

Febrile neutropenia (FN) is a frequent and often costly complication for patients with metastatic cancer receiving myelosuppressive chemotherapy. When patients develop FN, the likelihood...

Carfilzomib in Multiple Myeloma, New FDA App to Track Drug Shortages, and more

Carfilzomib Granted Priority Review in Relapsed Multiple Myeloma The U.S. Food and Drug Administration granted priority review status to the supplemental new drug application for...
WIB_icon

Novel Agent Attacks the Cause of Vaso-Occlusive Crisis in Sickle Cell Disease

Vaso-occlusive crisis (VOC) is a severely painful disease manifestation in adolescent and adult patients with sickle cell disease (SCD). Currently, treatment is limited to...

Ruxolitinib: Another Option for Polycythemia Vera Patients with Poor RESPONSE

Patients with polycythemia vera who do not respond well to hydroxyurea may have another promising treatment option, according to results from the RESPONSE trial. A...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.